Loading...

Pharnext

BST:P0X
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
P0X
BST
€233M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapeutics for severe orphan and common neurodegenerative diseases in France. The last earnings update was 182 days ago. More info.


Add to Portfolio Compare Print
  • Pharnext has significant price volatility in the past 3 months.
P0X Share Price and Events
7 Day Returns
1.4%
BST:P0X
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-
BST:P0X
-5.6%
DE Biotechs
-4.5%
DE Market
P0X Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pharnext (P0X) 1.4% 14.9% 10.4% - - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on P0X.
  • No trading data on P0X.
Price Volatility
P0X
Industry
5yr Volatility vs Market

Value

 Is Pharnext undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Pharnext is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Pharnext has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Pharnext. This is due to cash flow or dividend data being unavailable. The share price is €18.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pharnext's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pharnext's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:P0X PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-1.53
ENXTPA:ALPHA Share Price ** ENXTPA (2019-04-25) in EUR €17.85
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pharnext.

BST:P0X PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALPHA Share Price ÷ EPS (both in EUR)

= 17.85 ÷ -1.53

-11.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharnext is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Pharnext is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Pharnext's expected growth come at a high price?
Raw Data
BST:P0X PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-5.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pharnext, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pharnext's assets?
Raw Data
BST:P0X PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €-1.19
ENXTPA:ALPHA Share Price * ENXTPA (2019-04-25) in EUR €17.85
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
BST:P0X PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALPHA Share Price ÷ Book Value per Share (both in EUR)

= 17.85 ÷ -1.19

-15.05x

* Primary Listing of Pharnext.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharnext has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of P0X’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Pharnext's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Pharnext's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Pharnext has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pharnext expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pharnext expected to grow at an attractive rate?
  • Unable to compare Pharnext's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Pharnext's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Pharnext's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:P0X Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:P0X Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -5.6%
BST:P0X Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 60.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:P0X Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:P0X Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 14 -20 1
2019-12-31 0 -21 -21 1
2018-12-31 0 -22 -22 1
BST:P0X Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 7 -15 -18
2018-03-31 5 -17 -19
2017-12-31 3 -19 -20
2017-09-30 3 -20 -20
2017-06-30 4 -21 -20
2017-03-31 4 -17 -19
2016-12-31 4 -13 -17
2016-09-30 4 -10 -16
2016-06-30 3 -8 -14
2016-03-31 3 -9 -12
2015-12-31 3 -9 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pharnext is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Pharnext's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:P0X Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Pharnext Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:P0X Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31 -1.38 -1.38 -1.38 1.00
2018-12-31 -1.80 -1.80 -1.80 1.00
BST:P0X Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -1.53
2018-03-31 -1.61
2017-12-31 -1.85
2017-09-30 -1.77
2017-06-30 -1.81
2017-03-31 -1.71
2016-12-31 -2.07
2016-09-30 -1.45
2016-06-30 -2.15
2016-03-31 -1.93
2015-12-31 -1.71

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pharnext will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Pharnext's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pharnext has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pharnext performed over the past 5 years?

  • Pharnext's last earnings update was 182 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pharnext's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pharnext does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Pharnext's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pharnext's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Pharnext's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pharnext Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:P0X Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 6.92 -18.41 6.30 16.85
2018-03-31 5.12 -19.33 6.12 16.19
2017-12-31 3.32 -20.24 5.95 15.53
2017-09-30 3.48 -19.91 5.57 15.52
2017-06-30 3.64 -19.58 5.18 15.52
2017-03-31 4.03 -18.51 4.68 14.58
2016-12-31 4.42 -17.45 4.17 13.65
2016-09-30 3.90 -15.62 3.89 11.86
2016-06-30 3.37 -13.79 3.61 10.07
2016-03-31 3.00 -12.39 3.61 8.86
2015-12-31 2.63 -10.99 3.60 7.65
2014-12-31 2.70 -10.73 3.85 6.72
2013-12-31 2.63 -9.32 2.68 8.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pharnext has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Pharnext has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pharnext improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pharnext's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pharnext has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pharnext's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pharnext's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pharnext is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pharnext's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Pharnext's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Pharnext has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pharnext Company Filings, last reported 9 months ago.

BST:P0X Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -14.23 32.87 18.17
2018-03-31 -14.23 32.87 18.17
2017-12-31 -11.99 24.53 12.45
2017-09-30 -11.99 24.53 12.45
2017-06-30 -6.38 14.59 6.15
2017-03-31 -6.38 14.59 6.15
2016-12-31 3.80 12.32 16.67
2016-09-30 3.80 12.32 16.67
2016-06-30 -31.48 30.67 5.01
2016-03-31 -31.48 30.67 5.01
2015-12-31 -23.70 23.60 3.09
2014-12-31 -12.90 17.20 7.24
2013-12-31 -4.62 9.05 5.15
  • Pharnext has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Pharnext's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pharnext has sufficient cash runway for 1.2 years based on current free cash flow.
  • Pharnext has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 30.9% each year.
X
Financial health checks
We assess Pharnext's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pharnext has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pharnext's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pharnext dividends. Estimated to be 0% next year.
If you bought €2,000 of Pharnext shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pharnext's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pharnext's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:P0X Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:P0X Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pharnext has not reported any payouts.
  • Unable to verify if Pharnext's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pharnext's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pharnext has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Pharnext's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Pharnext's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pharnext afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pharnext has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pharnext's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Daniel Cohen
COMPENSATION €319,297
AGE 65
CEO Bio

Mr. Daniel E. Cohen, MD, PhD is President and Chief Executive Officer of MEDIKHMER PHARMACEUTICAL CO., LTD, is the pioneer of modern genetics and author of the first map of the human genome. He Co-Founded Millennium Pharmaceuticals, Inc., and Pharnext SAS. Mr. Cohen serves as Chief Executive Officer Pharnext SAS. He founded Modern Genetics, Genomics and Pharmacogenomics. He served as the Chief Scientific Officer of Serono Genetics Institute S.A. He joined Serono Genetics Institute S.A. in 1996 as Chief Genomics Officer and Director Général. He served as Vice President of Worldwide Genetics at Serono. He served as a Scientific Advisor for another genomics company. He established the most advanced physical map of the human genome in 1996, at the Foundation Jean Dausset, CEPH, where he worked as Scientific Director, which he co-founded. He serves as President of the Scientific Advisory Board at Molecular Engines Laboratories S.A. He served as the Chairman of Scientific Advisory Board of Moleac Pte Ltd. He serves as a Member of Scientific Advisory Board at Molecular Engines Laboratories S.A. He served as a Director at Serono Genetics Institute S.A. Mr. Cohen is a Professor of Medical Genetics at the University of Paris II. He has authored more than 100 scientific publications, 20 pharmaceutical patents and author of the first maps of the human genome and responsible for many discoveries in medical genetics. He is cited as an inventor on over 15 patents and the winner of many scientific prizes in France and internationally. He has received UNESCO's Prize of New Human Rights, the Daniel Bauperthuy Prize from the French Academy of Sciences for epidemiology and the Grand Prize for Medical Literature for the book, The Genes of Hope, which has been translated into seven languages. Mr. Cohen served as Chairman of Pharnext SAS. He received the Knight of the Legion of Honour (France) in 1998 and the American Academy of Achievement's Golden Plate Award in 1999. Mr. Cohen is a recognized world leader in the field of genomics. He is a Doctor Honoris Causa of Shanghai, Xi'an and Ben Gourion University. He has an M.D. and a Ph.D. in Immunology and Immunogenetics from the University of Paris VII.

CEO Compensation
  • Daniel's compensation has been consistent with company performance over the past year.
  • Daniel's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Pharnext management team in years:

0.3
Average Tenure
  • The average tenure for the Pharnext management team is less than 2 years, this suggests a new team.
Management Team

Daniel Cohen

TITLE
Co-Founder
COMPENSATION
€319K
AGE
65

Serguei Nabirotchkin

TITLE
Co-Founder & Chief Biology Officer

Ilya Chumakov

TITLE
Co-Founder

Amit Kohli

TITLE
Chief Operating Officer
TENURE
1 yrs

François Chamoun

TITLE
Legal Director & General Counsel

Xavier Paoli

TITLE
VP & Chief Commercial Officer

Serge Fitoussi

TITLE
Chief Medical Officer
TENURE
0.3 yrs

Susanne Dorn

TITLE
Chief Regulatory Officer

Rodolphe Hajj

TITLE
Chief Pharmacology Officer
TENURE
0.3 yrs
Board of Directors

Michel de Rosen

TITLE
Chairman
AGE
67

Daniel Cohen

TITLE
Co-Founder
COMPENSATION
€319K
AGE
65

Ilya Chumakov

TITLE
Co-Founder

Philippe Pouletty

TITLE
Director
AGE
60

Pierre Bastid

TITLE
Director
AGE
63

Christian Pierret

TITLE
Director
COMPENSATION
€13K

Nabil Sakkab

TITLE
Director
COMPENSATION
€4K
AGE
71

David Stout

TITLE
Director
AGE
63

Murielle Lemoine

TITLE
Director
AGE
49
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Pharnext's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pharnext has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapeutics for severe orphan and common neurodegenerative diseases in France. The company’s lead products include PXT3003 that is in Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big data genomics and artificial intelligence platform; and identifies and develops PLEODRUG, a combination of drugs. The company was founded in 2007 and is based in Issy-Les-Moulineaux, France.

Details
Name: Pharnext SA
P0X
Exchange: BST
Founded: 2007
€233,061,363
13,056,659
Website: http://www.pharnext.com
Address: Pharnext SA
11 rue des Peupliers,
Issy-Les-Moulineaux,
Ile-de-France, 92130,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALPHA Common Stock Euronext Paris FR EUR 18. Jul 2016
OTCPK PNEX.F Common Stock Pink Sheets LLC US USD 18. Jul 2016
BST P0X Common Stock Boerse-Stuttgart DE EUR 18. Jul 2016
Number of employees
Current staff
Staff numbers
0
Pharnext employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:27
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/24
Last earnings filing: 2018/10/25
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.